Health ❯ Healthcare ❯ Obesity

Treatment Options

Semaglutide Oral Medications GLP-1 Medications Weight Loss Injections GLP-1 Drugs GLP-1 Agonists Orforglipron Medication Injectable Medications GLP-1 Receptor Agonists

Boehringer’s Survodutide Cuts Body Weight 16.6% in Phase III Trial

The result strengthens Boehringer’s push to break into a market led by Eli Lilly and Novo Nordisk.

Amazon Pharmacy Launches Same-Day Delivery for Lilly’s Foundayo Weight-Loss Pill

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

FDA Clears Lilly’s Foundayo Pill, Escalating GLP-1 Weight-Loss Rivalry

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

India Tightens Oversight of GLP-1 Drugs as Semaglutide Generics Proliferate

FDA Clears 7.2‑mg Wegovy as India Enters Generic Semaglutide Era

Brazil's Semaglutide Patent Expires Friday, Opening Door to Ozempic Generics

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

Private GLP-1 Weight-Loss Use in UK Skews to Middle-Class Women, Analysis Shows

Boots Pilots First High‑Street Prescribing Service for Wegovy and Mounjaro

Anvisa Expands Wegovy and Ozempic Uses to Cardiovascular and Kidney Protection

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

New Review Finds Rapid Weight Return After Stopping GLP-1 Weight-Loss Drugs

Wegovy Pill Posts Strong U.S. Debut as U.K. Authorizes Higher 7.2 mg Injectable Dose

FDA Seeks Removal of Suicide Warnings From Saxenda, Wegovy and Zepbound

BMJ Review Flags Rapid Weight Regain After GLP‑1 Stop as UK Approves Higher‑Dose Wegovy

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price